CompletedPhase 2NCT01130519
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Studying Hereditary leiomyomatosis and renal cell cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ramaprasad Srinivasan, M.D.National Cancer Institute (NCI)
- Intervention
- Bevacizumab(drug)
- Enrollment
- 83 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2022
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01130519 on ClinicalTrials.gov